Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Roche-Lestienne

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Pathologie-Biologie|August 12, 2006
[Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera]C Roche-Lestienne, J Andrieux
Leukemia|January 26, 2007
The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?F E Nicolini, S Corm, Q-H Lê, et al.
Leukemia|February 23, 2018
Targeting MYC in multiple myelomaK K Jovanović, C Roche-Lestienne, I M Ghobrial, et al.
Leukemia|December 13, 2003
Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograftC Rose, S Dupire, C Roche-Lestienne, et al.
Leukemia|September 10, 2005
Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CMLS Corm, V Biggio, C Roche-Lestienne, et al.
Annales De Biologie Clinique|June 14, 2005
[Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition]M-P Moles, J Landry, C Roche-Lestienne, et al.
Oncogene|August 2, 2011
GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cellsS Joha, A-L Nugues, D Hétuin, et al.
Leukemia|June 4, 2011
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemiaC Roche-Lestienne, A Marceau, E Labis, et al.
Leukemia|October 25, 2016
The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myelomaS Manier, J T Powers, A Sacco, et al.
Leukemia|November 7, 2008
The molecular anatomy of the FIP1L1-PDGFRA fusion geneC Walz, J Score, J Mix, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Pathologie-Biologie|August 12, 2006
[Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera]C Roche-Lestienne, J Andrieux
Leukemia|January 26, 2007
The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?F E Nicolini, S Corm, Q-H Lê, et al.
Leukemia|February 23, 2018
Targeting MYC in multiple myelomaK K Jovanović, C Roche-Lestienne, I M Ghobrial, et al.
Leukemia|December 13, 2003
Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograftC Rose, S Dupire, C Roche-Lestienne, et al.
Leukemia|September 10, 2005
Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CMLS Corm, V Biggio, C Roche-Lestienne, et al.
Annales De Biologie Clinique|June 14, 2005
[Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition]M-P Moles, J Landry, C Roche-Lestienne, et al.
Oncogene|August 2, 2011
GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cellsS Joha, A-L Nugues, D Hétuin, et al.
Leukemia|June 4, 2011
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemiaC Roche-Lestienne, A Marceau, E Labis, et al.
Leukemia|October 25, 2016
The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myelomaS Manier, J T Powers, A Sacco, et al.
Leukemia|November 7, 2008
The molecular anatomy of the FIP1L1-PDGFRA fusion geneC Walz, J Score, J Mix, et al.
Pageof 2